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Identity 
Note 
Mastocytosis is a heterogeneous clinical entity which is 
classified into four categories: 
1- indolent mastocytosis (the most common form),  
2- mastocytosis with an associated hematologic 
disorder, 
3- mast cell leukemia and  
4- aggressive mastocytosis. 
Clinics and pathology 
Phenotype/cell stem origin 
Mast cell 
Etiology 
Involvement of KIT/SCF has been demonstrated in a 
few cases, but the diversity of the clinical pattern has 
not yet been elucidated;increased soluble SCF has been 
reported in the skin of patient with indolent 
mastocytosis; c-KIT mutations have been identified in 
patients with all forms of sporadic mastocytosis. 
Clinics 
Indolent mastocytosis involves the skin, bone marrow 
and gastrointestinal tract; clinical features range from a 
single cutaneous nodule to multiple pigmented macules 
resulting from increased epidermal melanin and 
papules (urticaria pigmentosa) or diffuse cutaneous 
involvement; bullae, vescicles and abnormal 
telangiectasia may be seen; gastrointestinal 
involvement leads to symptoms such as nausea, 
vomiting and abdominal pain.  
 
In mastocytosis with an associated hematological 
disorder the urticaria pigmentosa symptoms are 
accompanied by a variety of haematological findings 
due to mast cell infiltrates to bone marrow, spleen, liver 
and lymph nodes. 
Mast cell leukemia is characterized by proliferation and 
infiltration of immature mast cells in bone marrow, 
peripheral blood and various extramedullary tissues. 
Aggressive mastocytosis is characterized by aggressive 
involvement of several haematopoietic organs. 
Pathology 
Accumulation of mast cells in various organs and 
release of mast cell mediators which are responsible for 
the different clinical signs. 
Prognosis 
Highly dependent on the form being severe, often fatal, 
in all types with the exception of the indolent form. 
Genes involved and proteins 
KIT 
Location 
4q12 
DNA/RNA 
21 exons 
Protein 
Transmembrane SCF/MGF receptor with tyrosine 
kinase activity; binding of ligand (SCF) induces 
receptor dimerization, autophosphorylation and signal 
transduction via molecules containing SH2- domains. 
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Somatic mutations 
Gly560Val, Asp816Val, Asp816Tyr, Asp820Gly. 
Asp816Val in peripheral blood lymphocytes 
(mastocytosis with an associated hematological 
disorder: AHD). 
Asp816Val in skin and spleen mast cells from patients 
with aggressive mastocytosis. 
Asp816Tyr in blasts from a patient with ANLL-M2 
with mast cell involvement. 
Asp820 Gly in blasts from a patient with aggressive 
SMCD. 
Asp816Val and Gly560Val have been found in a 
human mast cell leukemia cell line (HMC1). 
Note 
All mutations with the exception of Gly560Val cluster 
to c-kit exon 17. Direct or indirect evidence has been 
provided that mutations affecting codon 816 promote 
ligand-independent autophosphorylation of the mutant 
receptor. 
SCF/MGF 
Location 
12q22 
DNA/RNA 
9 exons 
Protein 
Soluble SCF: 248 aminoacids containing a proteolytic 
cleavage site encoded by exon 6 sequences, which is 
processed, giving rise to an active form (soluble) of 165 
aminoacids; membrane-bound SCF: 220 aminoacids, 
results from alternative splicing of exon 6. 
Note: increased soluble SCF has been detected in the 
skin of patients with indolent mastocytosis; SCF-
specific transcripts are detected by in situ RT-PCR in 
mast cell infiltrates in papulae from mastocytosis 
patients. 
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